Overview

A Study to Evaluate a Chemotherapy Treatment Followed by Chemo and Radiotherapy in Patients With Rectal Cancer

Status:
Active, not recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

This is an exploratory, open-label, single arm, non-randomized, multicenter, phase II clinical trial to determine the efficacy and clinical complete response rate in patients with rectal cancer and tumor preoperative evaluation after NAC (Neoadjuvant Chemotherapy) with NALIRINOX (5-FU [fluorouracil)/LV [Leucovorin calcium] + oxaliplatin + nal-IRI [Liposomal Irinotecan]) and chemoradiotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

Fundación de investigación HM

Collaborator:

Syntax for Science, S.L

Treatments:

Oxaliplatin